LOKELMA DIN 02490714
Status: Marketed
Holder: ASTRAZENECA CANADA INC
Molecule: SODIUM ZIRCONIUM CYCLOSILICATE
Available to quote
Health Canada record
| Active ingredient(s) | SODIUM ZIRCONIUM CYCLOSILICATE 5 G |
|---|---|
| Dosage form | Powder For Suspension |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | V03AE10 SODIUM ZIRCONIUM CYCLOSILICATE |
| Original market date | 17-Oct-2019 |
| Current status date | 17-Oct-2019 |
| Source | Health Canada DPD |
Establishment licence of the holder
AstraZeneca Canada Inc. — licence 100421, currently licensed, last inspection rating C (2023-06-12).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing SODIUM ZIRCONIUM CYCLOSILICATE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02490722 | LOKELMA | ASTRAZENECA CANADA INC | Powder For Suspension | SODIUM ZIRCONIUM CYCLOSILICATE 10 G | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 22442 | 2019-07-25 | New Drug Submission (NDS) |
International API supply for SODIUM ZIRCONIUM CYCLOSILICATE
6 active FDA Drug Master Files.
Request a quote for LOKELMA